Our data show an increased vulnerability to COVID-19 in CLL patients during the Omicron pandemic, associated with age, TP53 disruption, prior treatment, and earlier phase of treatment with targeted agents. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.